White Shield

Interest-Based Ads

Advertising Cookies: We would like to set third-party advertising cookies on your browser for this health-related website to help us serve relevant health-related advertisements to you about our products or services when you visit other websites. For more information, visit our Privacy Policy. Do you want to set these advertising cookies on this browser?

Find A PLUVICTO Treatment Center
Patients HCP
This site is for US residents only.
PLUVICTO. Every day without progression is a VICTORY. Now available before chemotherapy for PSMA+ mCRPC* *For certain men as determined by their doctor.

After hormone therapy, men with PSMA+ mCRPC who received PLUVICTO saw:

More time without their cancer progressing, with a median of 9.3 months vs 5.6 months with a second hormone therapy

Their tumors shrink or disappear, 49% of the time vs 14% with a second hormone therapy

Ask about PLUVICTO. It’s not chemotherapy. It’s the FIRST and ONLY PSMA-targeted radioligand therapy.

Find out if PLUVICTO could be the next step for you or a loved one. Follow these links to explore why:

If you or a loved one has started on PLUVICTO, here's what you need to know:

Is PLUVICTO Right For Me?
Real Patient Stories
Dosing & Expectations
Novartis Patient Support™

Interested in receiving information about PLUVICTO?

PLUVICTO® Pulse provides educational support and materials for those considering and starting on treatment.

Sign Up Today
Watch the video to see what more time without progression could mean for you. 

mCRPC, metastatic castration-resistant resistant prostate cancer; PSMA+, prostate-specific membrane antigen positive.